Evoke Pharma (EVOK) Earning Somewhat Favorable Press Coverage, Study Shows
News articles about Evoke Pharma (NASDAQ:EVOK) have trended somewhat positive on Sunday, Accern Sentiment Analysis reports. The research firm rates the sentiment of press coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Evoke Pharma earned a news sentiment score of 0.08 on Accern’s scale. Accern also gave press coverage about the specialty pharmaceutical company an impact score of 44.9814988910934 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
These are some of the media headlines that may have effected Accern Sentiment’s scoring:
- EVOKE PHARMA, INC. – StreetInsider.com (streetinsider.com)
- Evoke Announces Discovery of Sex-Based Pharmacokinetic Differences for Gimoti™ (finance.yahoo.com)
- Evoke Pharma Inc (EVOK) Expected to Announce Earnings of -$0.22 Per Share (americanbankingnews.com)
- Evoke Pharma Inc (EVOK) Given Average Recommendation of “Buy” by Analysts (americanbankingnews.com)
Shares of Evoke Pharma (NASDAQ:EVOK) traded up $0.04 during trading hours on Friday, hitting $2.11. The stock had a trading volume of 188,369 shares, compared to its average volume of 84,385. The stock has a market capitalization of $32.52, a P/E ratio of -2.24 and a beta of 1.26. Evoke Pharma has a twelve month low of $2.07 and a twelve month high of $4.09.
Evoke Pharma Company Profile
Evoke Pharma, Inc is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.